Patient inaccessibility to antifungal drugs in developing nations: The case of Pakistan
The life threatening fungal infections are rising worldwide and becoming a challenging public health concern. Around 1.5 to 2 million people die each year globally due to fungal infections and Pakistan is not an exception.1 Fungal infections are common in Pakistan but are often under-diagnosed and under-reported. The population is at high risk due to high prevalence of fungal-infection-susceptible diseases such as cancer, diabetes, tuberculosis, chronic respiratory disorders, and asthma2. It has been estimated that around 3 million people in Pakistan are affected by fungal infections such as chronic pulmonary aspergillosis, mucormycosis, candidaemia, cryptococcal meningitis, pneumocystis pneumonia, oral candidiasis, and allergic fungal sinusitis.
Source: Research in Social and Administrative Pharmacy - Category: Pharmaceuticals Authors: Ahsan Saleem, Anam Khan, Akram Ahmad, Muhammad Umair Khan, Zaheer-Ud-Din Babar Source Type: research
More News: Allergy & Immunology | Aspergillosis | Cancer | Cancer & Oncology | Diabetes | Endocrinology | Fungal Infections | International Medicine & Public Health | Men | Meningitis | Oral Cancer | Pakistan Health | Pharmaceuticals | Pneumonia | Respiratory Medicine | Sinusitis | Tuberculosis